CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 28, 2015, Pages 8774-8779

  Smoum, Reem ^a   Baraghithy, Saja ^a   Chourasia, Mukesh ^a,d   Breuer, Aviva ^a   Mussai, Naama ^a   Attar Namdar, Malka ^a   Kogan, Natalya M ^a   Raphael, Bitya ^a   Bolognini, Daniele ^b,c   Cascio, Maria G ^b   Marini, Pietro ^b   Pertwee, Roger G ^b   Shurki, Avital ^a   Mechoulam, Raphael ^a   Bab, Itai ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d National Institutes of Pharmaceutical Education and Research   (India)

Author keywords

Enantiomers; Endocannabinoids; Osteoporosis; Pose occupancy

Indexed keywords

4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; COLONY STIMULATING FACTOR 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; HU 433; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG; CANNABINOID; CANNABINOID RECEPTOR AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG RECEPTOR BINDING; ENANTIOMER; FEMALE; HYDROPHOBICITY; MAST CELL; MOLECULAR MODEL; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OTITIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR AFFINITY; SINGLE DRUG DOSE; STEREOSPECIFICITY; AGONISTS; ANIMAL; C57BL MOUSE; CHEMISTRY; CHO CELL LINE; CRICETULUS; HAMSTER; METABOLISM; STEREOISOMERISM;

ANIMALIA;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CHO CELLS; CRICETINAE; CRICETULUS; MICE; MICE, INBRED C57BL; RECEPTOR, CANNABINOID, CB2; STEREOISOMERISM;

EID: 84937046436     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1503395112     Document Type: Article

References (49)

1. Pacher P, Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50(2):193-211.
2. Ofek O, et al. (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103(3):696-701.
3. Basu S, Ray A, Dittel BN (2011) Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol 187(11):5720-5732.
4. Galiègue S, et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232(1):54-61.
5. Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147(Suppl 1):S163-S171.
6. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: Role in central immune function. Br J Pharmacol 153(2):240-251.
7. Elphick MR, Egertová M (2001) The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 356(1407):381-408.
8. Rajesh M, et al. (2007) Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 82(6):1382-1389.
9. Toguri JT, et al. (2014) Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis. Br J Pharmacol 171(6):1448-1461.
10. Hanus L, et al. (1999) HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96(25):14228-14233.
11. Huffman JW, et al. (1999) 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7(12):2905-2914.
12. Horváth B, et al. (2012) A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol 165(8):2462-2478.
13. Han S, Thatte J, Buzard DJ, Jones RM (2013) Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem 56(21):8224-8256.
14. Ofek O, et al. (2011) CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res 26(2):308-316.
15. Arie¨ns EJ (1984) Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 26(6):663-668.
16. Tamura T, et al. (1993) New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro. J Bone Miner Res 8(8):953-960.
17. Zaidi M, Moonga BS, Huang CL (2004) Calcium sensing and cell signaling processes in the local regulation of osteoclastic bone resorption. Biol Rev Camb Philos Soc 79(1):79-100.
18. Sulcova E, Mechoulam R, Fride E (1998) Biphasic effects of anandamide. Pharmacol Biochem Behav 59(2):347-352.
19. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008) Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 20(Suppl 1):69-74.
20. 2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol 24(4):608-620.
21. Mimura T, Ueda Y, Watanabe Y, Sugiura T (2012) The cannabinoid receptor-2 is involved in allergic inflammation. Life Sci 90(21-22):862-866.
22. Kou J, et al. (2005) Anti-inflammatory activities of aqueous extract from Radix Ophiopogon japonicus and its two constituents. Biol Pharm Bull 28(7):1234-1238.
23. Włodarski KH (1990) Properties and origin of osteoblasts. Clin Orthop Relat Res (252):276-293.
24. Kurihara N, et al. (1989) Generation of osteoclasts from isolated hematopoietic progenitor cells. Blood 74(4):1295-1302.
25. Prussin C, Metcalfe DD (2003) 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 111(2, Suppl):S486-S494.
26. Palczewski K, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289(5480):739-745.
27. Xie X-Q, Chen J-Z, Billings EM (2003) 3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins 53(2):307-319.
28. Hurst DP, et al. (2010) A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 285(23):17954-17964.
29. Zhang R, Xie X (2012) Tools for GPCR drug discovery. Acta Pharmacol Sin 33(3):372-384.
30. Pacher P, Kunos G (2013) Modulating the endocannabinoid system in human health and disease - successes and failures. FEBS J 280(9):1918-1943.
31. Ross RA, et al. (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126(3):665-672.
32. Thomas A, et al. (2005) Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146(7):917-926.
33. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23):3099-3108.
34. Bolognini D, Cascio MG, Parolaro D, Pertwee RG (2012) AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol 165(8):2561-2574.
35. Kato M, et al. (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157(2):303-314.
36. Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40(2):251-264.
37. Bajayo A, et al. (2005) Central IL-1 receptor signaling regulates bone growth and mass. Proc Natl Acad Sci USA 102(36):12956-12961.
38. Yirmiya R, et al. (2006) Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci USA 103(45):16876-16881.
39. Parfitt AM, et al.; Report of the ASBMR Histomorphometry Nomenclature Committee (1987) Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2(6):595-610.
40. Magrane M, Consortium U (2011) UniProt Knowledgebase: A hub of integrated protein data. Database (Oxford) 2011:bar009.
41. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234(3):779-815.
42. Choi G, Landin J, Xie XQ (2002) The cytoplasmic helix of cannabinoid receptor CB2, a conformational study by circular dichroism and (1)H NMR spectroscopy in aqueous and membrane-like environments. J Pept Res 60(3):169-177.
43. Frisch MJ, et al. (2009) Gaussian 09, Revision D.01 (Gaussian, Wallingford, CT).
44. Morris GM, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30(16):2785-2791.
45. Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36(22):3219-3228.
46. Wang J, Kollman PA, Kuntz ID (1999) Flexible ligand docking: A multistep strategy approach. Proteins-Structure Function and Genetics 36(1):1-19.
47. Dundas J, et al. (2006) CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 34(Web Server Issue):W116-8.
48. Zhang Y, et al. (2011) Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. Int Immunopharmacol 11(9):1303-1310.
49. Poso A, Huffman JW (2008) Targeting the cannabinoid CB2 receptor: Modelling and structural determinants of CB2 selective ligands. Br J Pharmacol 153(2):335-346.